C1QTNF9 and diabetes mellitus: To determine the anti-senescence effect of CTRP9 in the context of atherosclerotic plaque formation, Lv-CTRP9 and Lv-GFP were injected via the tail vein into ApoE KO mice with STZ-induced diabetes (Figure 6).